The head of the Corona vaccine trial team in Oxford confirmed that face masks and social distancing will be needed until next summer and Andrew Pollard warned of the need to follow strict rules even if global tests prove successful, and said that the first doses of the vaccine will likely not be available until next year – and after That’s only for major groups like doctors on the front lines of treating Corona.
According to the British newspaper, “Daily Mail”, Professor Pollard said that he hopes to complete the final experiments by the end of this year, but added: “Life will not return to normal until the summer at the earliest. We may need masks until next July.”
“If we do end up with a vaccine that is effective in preventing disease, this is the best way to control the virus. But in the medium term, we will still need better treatments. When will life return to normal? Even if we have enough vaccine for everyone, it is unlikely.” My view is that we will be very fast in a situation where the rules of physical distancing can be dropped. “
“Until we get a high level of immunity in the population so that we can stop the virus so that the most vulnerable people are immune, there will be risks. In the beginning, we will be in a situation where wearing the mask and social distancing do not change.”
Only when there is a significant reduction in severe cases will governments feel able to relax these measures.
The Oxford University Vaccine, which was produced using the giant drugs AstrazenecaIt is one of only nine vaccines to have reached the third stage of trials, which is the last stage before implementation, and is widely seen as the leading candidate for submission.
–
The professor indicated that launching the vaccine would be a “major challenge” in his remarks to a webinar with Oxford alumni. Professor Pollard explained that if the vaccine is successful, it will need approval from the Medicines and Healthcare Products Regulatory Agency.
He said, ‘Once we get the results of the experiment, I can’t imagine they’ll do it overnight. They’ll have to examine the data very carefully – the public won’t expect less.’
He said the final evaluation will likely take weeks, though he and his team have launched a “rolling program” to give the regulatory agency access to trials while in progress.
–
– .
